Background: PTCL is an aggressive form of non-Hodgkin lymphoma (NHL), accounting for 5-10% of NHL diagnoses. Standard NHL therapies developed primarily for B-cell lymphomas are not optimal for PTCL and early relapse is common. Only a minority of pts are eligible for bone marrow transplantation and the majority of transplanted pts will relapse. Approved therapies for rel/ref PTCL in the USA include pralatrexate and romidepsin; elsewhere, gemcitabine is frequently used although not approved for this indication. The oral, investigational drug alisertib is a selective inhibitor of Aurora A kinase ( 
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